NCT03895944View on ClinicalTrials.gov

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
CD19+ Lymphoma, B-CellCD19+ Leukemia, B-Cell
Interventions
BIOLOGICAL

ET190L1-ARTEMIS™ T cells -iv low dose

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6

BIOLOGICAL

ET190L1-ARTEMIS™ T cells -iv middle dose

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6

BIOLOGICAL

ET190L1-ARTEMIS™ T cells - iv high dose

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6

Trial Locations (1)

710061

RECRUITING

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sponsors

Collaborators (1)

Eureka Therapeutics Inc.
All Listed Sponsors
collaborator

Eureka Therapeutics Inc.

INDUSTRY

lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER